{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:31:58Z","timestamp":1792643518191,"version":"4.5.0"},"reference-count":133,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"\n Importance<\/jats:title>\n Placebo is the only substance systematically evaluated across common psychiatric diagnoses, but comprehensive cross-diagnostic comparisons are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare changes in placebo groups in recent high-quality randomized clinical trials (RCTs) across a broad spectrum of psychiatric disorders in adult patients.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n MEDLINE and the Cochrane Database of Systematic Reviews were systematically searched in March 2022 for the latest systematic reviews meeting predetermined high-quality criteria for 9 major psychiatric diagnoses.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Using these reviews, the top 10 highest-quality (ie, lowest risk of bias, according to the Cochrane Risk of Bias tool) and most recent placebo-controlled RCTs per diagnosis (totaling 90 RCTs) were selected, adhering to predetermined inclusion and exclusion criteria.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Following the Cochrane Handbook, 2 authors independently carried out the study search, selection, and data extraction. Cross-diagnosis comparisons were based on standardized pre-post effect sizes (mean change divided by its SD) for each placebo group. This study is reported following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measure<\/jats:title>\n \n The primary outcome, pooled pre-post placebo effect sizes (\n \n d\n av<\/jats:sub>\n <\/jats:italic>\n ) with 95% CIs per diagnosis, was determined using random-effects meta-analyses. A\n Q<\/jats:italic>\n test assessed statistical significance of differences across diagnoses. Heterogeneity and small-study effects were evaluated as appropriate.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 90 RCTs with 9985 placebo-treated participants were included. Symptom severity improved with placebo in all diagnoses. Pooled pre-post placebo effect sizes differed across diagnoses (\n Q<\/jats:italic>\n \u2009=\u200988.5;\n df<\/jats:italic>\n \u2009=\u20098;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), with major depressive disorder (\n \n d\n av<\/jats:sub>\n <\/jats:italic>\n \u2009=\u20091.40; 95% CI, 1.24-1.56) and generalized anxiety disorder (\n \n d\n av<\/jats:sub>\n <\/jats:italic>\n \u2009=\u20091.23; 95% CI, 1.06-1.41) exhibiting the largest\n \n d\n av<\/jats:sub>\n <\/jats:italic>\n . Panic disorder, attention-deficit\/hyperactivity disorder, posttraumatic stress disorder, social phobia, and mania showed\n \n d\n av<\/jats:sub>\n <\/jats:italic>\n between 0.68 and 0.92, followed by OCD (\n \n d\n av<\/jats:sub>\n <\/jats:italic>\n \u2009=\u20090.65; 95% CI, 0.51-0.78) and schizophrenia (\n \n d\n av<\/jats:sub>\n <\/jats:italic>\n \u2009=\u20090.59; 95% CI, 0.41-0.76).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n This systematic review and meta-analysis found that symptom improvement with placebo treatment was substantial in all conditions but varied across the 9 included diagnoses. These findings may help in assessing the necessity and ethical justification of placebo controls, in evaluating treatment effects in uncontrolled studies, and in guiding patients in treatment decisions. These findings likely encompass the true placebo effect, natural disease course, and nonspecific effects.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2024.0994","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T11:01:42Z","timestamp":1716980502000},"page":"757","source":"Crossref","is-referenced-by-count":77,"title":["Differential Outcomes of Placebo Treatment Across 9 Psychiatric Disorders"],"prefix":"10.1001","volume":"81","author":[{"given":"Tom","family":"Bschor","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Hospital, Technical University of Dresden, Dresden, Germany"},{"name":"Government Commission for Modern and Needs-Based Hospital Care, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Nagel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Hospital, Technical University of Dresden, Dresden, Germany"},{"name":"Federal Joint Committee (G-BA), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Unger","sequence":"additional","affiliation":[{"name":"Social Psychiatric Service, Berlin district of Reinickendorf, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Schwarzer","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Baethge","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"yoi240022r1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.NMD.0000061144.16176.38","article-title":"Placebo response and antidepressant clinical trial outcome.","volume":"191","author":"Khan","year":"2003","journal-title":"J Nerv Ment Dis"},{"issue":"11","key":"yoi240022r2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2174\/156802605774297092","article-title":"Is there a placebo problem in antidepressant trials?","volume":"5","author":"Yang","year":"2005","journal-title":"Curr Top Med Chem"},{"issue":"10","key":"yoi240022r3","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.4088\/JCP.11r07485","article-title":"Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.","volume":"73","author":"Iovieno","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"14","key":"yoi240022r4","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing.","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"yoi240022r5","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1345\/aph.1D172","article-title":"Meta-analysis of placebo rates in major depressive disorder trials.","volume":"37","author":"Stolk","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"1-3","key":"yoi240022r6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2009.01.029","article-title":"Meta-analysis of the placebo response in antidepressant trials.","volume":"118","author":"Rief","year":"2009","journal-title":"J Affect Disord"},{"issue":"12","key":"yoi240022r7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: a meta-analysis.","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi240022r9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it.","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"issue":"5","key":"yoi240022r10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1017\/S0033291704003873","article-title":"Magnitude of placebo response and drug-placebo differences across psychiatric disorders.","volume":"35","author":"Khan","year":"2005","journal-title":"Psychol Med"},{"issue":"11","key":"yoi240022r11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","article-title":"Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies.","volume":"3","author":"Furukawa","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"yoi240022r12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jad.2017.03.024","article-title":"Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder: a meta-regression analysis.","volume":"215","author":"Meister","year":"2017","journal-title":"J Affect Disord"},{"issue":"10","key":"yoi240022r13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40263-019-00662-y","article-title":"Meta-analysis of placebo response in adult antidepressant trials.","volume":"33","author":"Li","year":"2019","journal-title":"CNS Drugs"},{"issue":"9","key":"yoi240022r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.25531","article-title":"Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis.","volume":"4","author":"Jones","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"yoi240022r15","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/ije\/dyy076","article-title":"Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis.","volume":"47","author":"Salanti","year":"2018","journal-title":"Int J Epidemiol"},{"issue":"1","key":"yoi240022r16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12888-020-02839-y","article-title":"Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials.","volume":"20","author":"Holper","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"8","key":"yoi240022r17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0006-3223(99)00311-X","article-title":"Placebo effect in randomized, controlled studies of acute bipolar mania and depression.","volume":"47","author":"Keck","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"8","key":"yoi240022r18","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1176\/appi.ajp.161.8.1485","article-title":"Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder.","volume":"161","author":"Huppert","year":"2004","journal-title":"Am J Psychiatry"},{"key":"yoi240022r19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jad.2017.04.068","article-title":"Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis.","volume":"218","author":"Sugarman","year":"2017","journal-title":"J Affect Disord"},{"issue":"1","key":"yoi240022r20","doi-asserted-by":"publisher","first-page":"21301","DOI":"10.1038\/s41598-021-99534-z","article-title":"Differential power of placebo across major psychiatric disorders: a preliminary meta-analysis and machine learning study.","volume":"11","author":"Cao","year":"2021","journal-title":"Sci Rep"},{"issue":"10128","key":"yoi240022r21","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"yoi240022r22","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","article-title":"Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.","volume":"27","author":"Kishi","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"10202","key":"yoi240022r23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"yoi240022r24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.","volume":"3","author":"Skapinakis","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"yoi240022r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240584","article-title":"Pharmacologic treatment of attention deficit hyperactivity disorder in adults: a systematic review and network meta-analysis.","volume":"15","author":"Elliott","year":"2020","journal-title":"PLoS One"},{"key":"yoi240022r26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.580858","article-title":"Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials.","volume":"11","author":"Kong","year":"2020","journal-title":"Front Pharmacol"},{"issue":"4","key":"yoi240022r27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1017\/neu.2020.6","article-title":"Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis.","volume":"32","author":"Williams","year":"2020","journal-title":"Acta Neuropsychiatr"},{"key":"yoi240022r28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066084","article-title":"Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials.","volume":"376","author":"Chawla","year":"2022","journal-title":"BMJ"},{"issue":"3","key":"yoi240022r29","article-title":"Pharmacotherapy for post traumatic stress disorder (PTSD).","volume":"3","author":"Williams","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"yoi240022r30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"yoi240022r31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1503\/jpn","article-title":"Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.","volume":"39","author":"Bakish","year":"2014","journal-title":"J Psychiatry Neurosci"},{"issue":"7","key":"yoi240022r32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"yoi240022r33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.","volume":"16","author":"Jain","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"yoi240022r34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.euroneuro.2005.09.002","article-title":"Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.","volume":"16","author":"Kennedy","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"yoi240022r35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-244X-13-94","article-title":"A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg\/day in adult outpatients with major depressive disorder.","volume":"13","author":"Liebowitz","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"5","key":"yoi240022r36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4088\/JCP.14m09337","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.","volume":"76","author":"Mahableshwarkar","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"yoi240022r37","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.","volume":"17","author":"McIntyre","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"yoi240022r38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hup.v27.1","article-title":"Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.","volume":"27","author":"Oakes","year":"2012","journal-title":"Hum Psychopharmacol"},{"issue":"5","key":"yoi240022r39","first-page":"661","article-title":"Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.","volume":"10","author":"Oli\u00e9","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1-2","key":"yoi240022r40","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jad.2010.06.030","article-title":"Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study.","volume":"136","author":"Berwaerts","year":"2012","journal-title":"J Affect Disord"},{"issue":"1","key":"yoi240022r41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bdi.2006.8.issue-1","article-title":"Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials.","volume":"8","author":"Kushner","year":"2006","journal-title":"Bipolar Disord"},{"key":"yoi240022r42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2015.06.059","article-title":"Asenapine: efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.","volume":"190","author":"Landbloom","year":"2016","journal-title":"J Affect Disord"},{"issue":"4","key":"yoi240022r43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/01.jcp.0000169068.34322.70","article-title":"Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.","volume":"25","author":"Potkin","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"yoi240022r44","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.4088\/JCP.v69n1113","article-title":"Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.","volume":"69","author":"Tohen","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"yoi240022r45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bdi.2010.12.issue-3","article-title":"A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.","volume":"12","author":"Vieta","year":"2010","journal-title":"Bipolar Disord"},{"issue":"3","key":"yoi240022r46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/archgenpsychiatry.2007.43","article-title":"Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen.","volume":"65","author":"Yildiz","year":"2008","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"yoi240022r47","first-page":"54","article-title":"Efficacy and safety of paliperidone extended release 1.5 mg\/day\u2014a double-blind, placebo- and active-controlled, study in the treatment of patients with schizophrenia.","volume":"44","author":"Coppola","year":"2011","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"yoi240022r48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/hup.v28.2","article-title":"Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.","volume":"28","author":"Egan","year":"2013","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"yoi240022r49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial.","volume":"35","author":"Kane","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"1-3","key":"yoi240022r50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","article-title":"Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.","volume":"174","author":"Kane","year":"2016","journal-title":"Schizophr Res"},{"issue":"2","key":"yoi240022r51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/JCP.0000000000000071","article-title":"The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.","volume":"34","author":"Litman","year":"2014","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"yoi240022r52","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.4088\/JCP.16m10698","article-title":"Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study.","volume":"77","author":"Loebel","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"yoi240022r53","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi240022r54","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"3","key":"yoi240022r55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"yoi240022r56","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/2045125315606027","article-title":"A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia.","volume":"5","author":"Potkin","year":"2015","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"yoi240022r58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/00004850-199603000-00003","article-title":"Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.","volume":"11","author":"Goodman","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"yoi240022r59","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4088\/JCP.v64n0919","article-title":"Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.","volume":"64","author":"Hollander","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"yoi240022r60","doi-asserted-by":"publisher","first-page":"640","DOI":"10.4088\/JCP.v64n0604","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.","volume":"64","author":"Hollander","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"yoi240022r61","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/pcn.2004.58.issue-4","article-title":"Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.","volume":"58","author":"Kamijima","year":"2004","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"yoi240022r62","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00004850-200511000-00003","article-title":"St John\u2019s wort versus placebo in obsessive-compulsive disorder: results from a double-blind study.","volume":"20","author":"Kobak","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"yoi240022r63","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/00004714-199904000-00013","article-title":"Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.","volume":"19","author":"Kronig","year":"1999","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi240022r64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","article-title":"A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder.","volume":"3","author":"Montgomery","year":"1993","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"yoi240022r65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.","volume":"16","author":"Montgomery","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"yoi240022r66","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.","volume":"23","author":"Stein","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"yoi240022r67","doi-asserted-by":"publisher","first-page":"694","DOI":"10.4088\/JCP.12m08144","article-title":"Lisdexamfetamine dimesylate in adults with attention-deficit\/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.","volume":"74","author":"Adler","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"yoi240022r68","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/15622975.2011.600333","article-title":"Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit\/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.","volume":"14","author":"Casas","year":"2013","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"yoi240022r69","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/1087054717696771","article-title":"Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: results of a phase 3, double-blind, randomized, forced-dose trial.","volume":"24","author":"Frick","year":"2020","journal-title":"J Atten Disord"},{"issue":"1","key":"yoi240022r70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4088\/JCP.15m10348","article-title":"Randomized, 6-week, placebo-controlled study of treatment for adult attention-deficit\/hyperactivity disorder: individualized dosing of osmotic-release oral system (OROS) methylphenidate with a goal of symptom remission.","volume":"78","author":"Goodman","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi240022r71","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/1087054713510352","article-title":"Efficacy and safety of atomoxetine hydrochloride in Asian adults with ADHD.","volume":"21","author":"Goto","year":"2017","journal-title":"J Atten Disord"},{"issue":"1","key":"yoi240022r72","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12325-013-0085-5","article-title":"Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.","volume":"31","author":"Huss","year":"2014","journal-title":"Adv Ther"},{"issue":"10","key":"yoi240022r73","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.biopsych.2007.11.008","article-title":"A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit\/hyperactivity disorder.","volume":"63","author":"Medori","year":"2008","journal-title":"Biol Psychiatry"},{"issue":"6","key":"yoi240022r74","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3109\/15622975.2013.868925","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit\/hyperactivity disorder in Japan.","volume":"15","author":"Takahashi","year":"2014","journal-title":"World J Biol Psychiatry"},{"issue":"5","key":"yoi240022r75","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2165\/11631990-000000000-00000","article-title":"Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.","volume":"26","author":"Weisler","year":"2012","journal-title":"CNS Drugs"},{"issue":"8","key":"yoi240022r76","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40263-017-0455-7","article-title":"Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit\/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled, forced-dose clinical study.","volume":"31","author":"Weisler","year":"2017","journal-title":"CNS Drugs"},{"issue":"12","key":"yoi240022r77","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.","volume":"22","author":"Bidzan","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"yoi240022r78","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1017\/S1461145714000017","article-title":"Lavender oil preparation Silexan is effective in generalized anxiety disorder\u2014a randomized, double-blind comparison to placebo and paroxetine.","volume":"17","author":"Kasper","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"yoi240022r79","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.","volume":"68","author":"Mahableshwarkar","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"2","key":"yoi240022r80","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1017\/S0033291708003401","article-title":"Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.","volume":"39","author":"Nicolini","year":"2009","journal-title":"Psychol Med"},{"issue":"3","key":"yoi240022r81","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/JCP.0b013e318172b45f","article-title":"Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.","volume":"28","author":"Pollack","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"yoi240022r82","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"yoi240022r83","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.","volume":"28","author":"Stein","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"yoi240022r84","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.","volume":"75","author":"Stein","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi240022r85","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.euroneuro.2017.02.007","article-title":"Efficacy and safety of agomelatine (10 or 25 mg\/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study.","volume":"27","author":"Stein","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"yoi240022r86","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/hup.v19:6","article-title":"Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.","volume":"19","author":"Allgulander","year":"2004","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"yoi240022r87","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1185\/03007995.2016.1146663","article-title":"A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan.","volume":"32","author":"Asakura","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"yoi240022r88","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phobia\/social anxiety disorder: randomised, double-blind, placebo-controlled study.","volume":"175","author":"Baldwin","year":"1999","journal-title":"Br J Psychiatry"},{"issue":"6","key":"yoi240022r89","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","article-title":"Treatment of social phobia with clonazepam and placebo.","volume":"13","author":"Davidson","year":"1993","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi240022r90","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/01.jcp.0000106222.36344.96","article-title":"Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.","volume":"24","author":"Davidson","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi240022r91","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4088\/JCP.v65n0213","article-title":"Controlled-release paroxetine in the treatment of patients with social anxiety disorder.","volume":"65","author":"Lepola","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"yoi240022r92","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1192\/bjp.172.1.70","article-title":"Placebo-controlled trial of moclobemide in social phobia.","volume":"172","author":"Schneier","year":"1998","journal-title":"Br J Psychiatry"},{"issue":"8","key":"yoi240022r93","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.","volume":"280","author":"Stein","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"yoi240022r94","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","article-title":"Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.","volume":"177","author":"Stein","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"yoi240022r95","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4088\/JCP.08m04949gre","article-title":"Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial.","volume":"71","author":"Stein","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi240022r96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Res"},{"issue":"5","key":"yoi240022r97","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/archpsyc.1988.01800290027004","article-title":"Alprazolam in panic disorder and agoraphobia: results from a multicenter trial\u2014I: efficacy in short-term treatment.","volume":"45","author":"Ballenger","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"yoi240022r98","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.","volume":"155","author":"Ballenger","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi240022r99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/acp.1999.99.issue-1","article-title":"Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study.","volume":"99","author":"Caillard","year":"1999","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"yoi240022r100","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4088\/JCP.08m04238","article-title":"A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder.","volume":"70","author":"Liebowitz","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"yoi240022r101","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1176\/ajp.155.11.1570","article-title":"Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo.","volume":"155","author":"Michelson","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"8","key":"yoi240022r102","first-page":"349","article-title":"Diazepam versus alprazolam for the treatment of panic disorder.","volume":"57","author":"Noyes","year":"1996","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"yoi240022r103","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1176\/ajp.155.9.1189","article-title":"Sertraline in the treatment of panic disorder: a double-blind multicenter trial.","volume":"155","author":"Pohl","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"11","key":"yoi240022r104","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.","volume":"55","author":"Pollack","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"yoi240022r105","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4088\/JCP.v66n0105","article-title":"Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.","volume":"66","author":"Sheehan","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"yoi240022r106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1192\/bjp.175.1.17","article-title":"Fluoxetine in post-traumatic stress disorder: randomised, double-blind study.","volume":"175","author":"Connor","year":"1999","journal-title":"Br J Psychiatry"},{"issue":"10","key":"yoi240022r107","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1001\/archpsyc.63.10.1158","article-title":"Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.","volume":"63","author":"Davidson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"yoi240022r108","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/JCP.0b013e318160f83b","article-title":"Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population.","volume":"28","author":"Davis","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"yoi240022r110","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13267","article-title":"A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in veterans.","volume":"81","author":"Davis","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi240022r111","doi-asserted-by":"publisher","first-page":"711","DOI":"10.4088\/JCP.v68n0508","article-title":"Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting.","volume":"68","author":"Friedman","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi240022r112","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/13651501.2017.1291838","article-title":"Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study.","volume":"21","author":"Li","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"6","key":"yoi240022r113","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of prazosin for post-traumatic stress disorder in military veterans.","volume":"378","author":"Raskind","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"yoi240022r114","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00213-017-4649-y","article-title":"A randomized controlled trial of ganaxolone in posttraumatic stress disorder.","volume":"234","author":"Rasmusson","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"yoi240022r115","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2016.15070967","article-title":"Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial.","volume":"173","author":"Villarreal","year":"2016","journal-title":"Am J Psychiatry"},{"key":"yoi240022r116","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"yoi240022r117","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"ROB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"yoi240022r118","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs.","volume":"4","author":"Lakens","year":"2013","journal-title":"Front Psychol"},{"issue":"2","key":"yoi240022r122","doi-asserted-by":"publisher","DOI":"10.1037\/1522-3736.1.1.12a","article-title":"Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication.","volume":"1","author":"Kirsch","year":"1998","journal-title":"Prev Treat"},{"issue":"1","key":"yoi240022r123","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.biopsych.2020.01.012","article-title":"Causes and consequences of diagnostic heterogeneity in depression: paths to discovering novel biological depression subtypes.","volume":"88","author":"Lynch","year":"2020","journal-title":"Biol Psychiatry"},{"issue":"6","key":"yoi240022r124","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia.","volume":"39","author":"J\u00e4\u00e4skel\u00e4inen","year":"2013","journal-title":"Schizophr Bull"},{"key":"yoi240022r125","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-0716-1566-9","article-title":"Meta-analysis of proportions.","volume":"2345","author":"Schwarzer","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"3","key":"yoi240022r126","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4088\/JCP.08r04516blu","article-title":"Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials: results from pooled and meta-analyses.","volume":"71","author":"Sinyor","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"yoi240022r127","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1176\/ajp.145.6.684","article-title":"Gender differences in the course of schizophrenia.","volume":"145","author":"Goldstein","year":"1988","journal-title":"Am J Psychiatry"},{"issue":"6","key":"yoi240022r128","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.eurpsy.2003.06.001","article-title":"Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample.","volume":"18","author":"Usall","year":"2003","journal-title":"Eur Psychiatry"},{"issue":"1","key":"yoi240022r129","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/bmjebm-2021-111861","article-title":"Proportion attributable to contextual effects in general medicine: a meta-epidemiological study based on Cochrane reviews.","volume":"28","author":"Tsutsumi","year":"2023","journal-title":"BMJ Evid Based Med"},{"issue":"3","key":"yoi240022r130","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/acps.2014.130.issue-3","article-title":"Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis.","volume":"130","author":"Furukawa","year":"2014","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"yoi240022r131","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000346144","article-title":"Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000-2010.","volume":"82","author":"Baethge","year":"2013","journal-title":"Psychother Psychosom"},{"issue":"4","key":"yoi240022r132","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/jamapsychiatry.2014.2206","article-title":"Identification of a common neurobiological substrate for mental illness.","volume":"72","author":"Goodkind","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"yoi240022r133","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00702-022-02567-5","article-title":"Neurodevelopmental disturbances in schizophrenia: evidence from genetic and environmental factors.","volume":"130","author":"Schmitt","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"yoi240022r8","volume-title":"Persuasion and Healing: A Comparative Study of Psychotherapy","author":"Frank","year":"1991","edition":"3rd ed"},{"key":"yoi240022r119","first-page":"290","volume-title":"Understanding the New Statistics: Effect Sizes, Confidence Intervals, and Meta-Analysis","author":"Cumming","year":"2012"},{"key":"yoi240022r121","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","edition":"2nd ed"},{"key":"yoi240022r57","unstructured":"GlaxoSmithKline. Paroxetine versus clomipramine and placebo in the treatment of obsessive-compulsive disorder. 2005; https:\/\/filehosting-v2.pharmacm.com\/api\/Attachment\/Download?tenantId=80217381&parentIdentifier=29060\/118&attachmentIdentifier=e00bb55b-2137-4c03-8f11-65284493ba05&fileName=2168.pdf&versionIdentifier="},{"key":"yoi240022r109","unstructured":"Davis? L. Nepicastat for posttraumatic stress disorder (PTSD) in OIF\/OEF veterans (Nepicastat). Accessed February 21, 2024. https:\/\/clinicaltrials.gov\/study\/NCT00659230?tab=results"},{"key":"yoi240022r120","unstructured":"MOTE. Magnitude of effect size calculator, version 2. Accessed April 25, 2024. https:\/\/doomlab.shinyapps.io\/mote\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2818945\/jamapsychiatry_bschor_2024_oi_240022_1721838745.04707.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T11:06:32Z","timestamp":1723028792000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2818945"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":133,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0994","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}